NCT01395264

Brief Summary

Migraine is one of the commonest neurological disorders, affecting up to 12% of the general population, but remains relatively under-diagnosed and under-treated. Migraine has a wide socioeconomic impact and brings a large economic burden; estimates suggest that disability due to migraine costs \> €27 billion per annum across Europe. Despite its prevalence and impact, migraine pathophysiology is poorly understood. A wider understanding of the functional changes in this disorder would be beneficial to both diagnosis and treatment. Saccades are the rapid eye movements we make when moving the eyes to a new object in our visual field. Reaction time studies have been used to investigate Huntington's disease and Parkinson's disease with great success. These use saccadic tasks (monitoring eye movements). Even at rest we make approximately three saccades per second, so a lot of data can quickly be gathered with non-invasive testing. We hope to understand more of the underlying mechanisms of migraine by studying reaction time in migraine patients. Our previous pilot study, with less stringent inclusion and exclusion criteria, looked at fewer patients (32 migraineurs and 32 controls), and found that migraineurs showed significantly different saccadic patterns to non-migraineurs. This study firstly seeks to corroborate the saccadometric findings of our earlier pilot study in a group of migraineurs, and secondly to explore the specificity of these findings in migraine by also studying patients with another primary headache syndrome, namely cluster headache. Migraine is known to be a dynamic disorder, with previous studies showing longitudinal changes in the migraine brain. To explore this further we hope to record longitudinally (Every day for 21 days) in a small subset of migraineurs to identify potential longitudinal changes in saccadic reaction time. Because of the portability of the equipment this could be done in the subjects own home if they preferred.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2011

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 14, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 15, 2011

Completed
17 days until next milestone

Study Start

First participant enrolled

August 1, 2011

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 27, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 27, 2017

Completed
Last Updated

October 31, 2017

Status Verified

October 1, 2017

Enrollment Period

6.2 years

First QC Date

July 14, 2011

Last Update Submit

October 27, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • To see if Saccadometry results differ between controls and migraine subjects

    By May 2019

Study Arms (4)

Episodic Migraine.

menstrual migraine

Cluster Headache patients

control (non-headache group)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

From hospital Headache clinics (secondary and tertiary)

You may qualify if:

  • Male or female and aged between 18 and 60 years in good general health apart from suffering from headaches (test group).
  • Migraine and cluster headache will be diagnosed according to ICHD-II diagnostic criteria (6).
  • Migraineurs must suffer at least two migraine attacks per year and no more than 5 attacks per month.

You may not qualify if:

  • Any other neurological disorder such as stroke, multiple sclerosis, epilepsy, concussion within the past year, psychiatric disorders, visual disorders.
  • Use of migraine prophylactic medication in the last month or acute migraine therapy in the 3 days prior to testing.
  • Patients on any medication to treat depression in their case
  • Headache during testing or within 3 days before and after testing.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Neurology Department, Whittington Hospital

London, N19 5NF, United Kingdom

Location

The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, and The John Radcliffe hospital, Oxford, The Whittington Hospital N19 5NF London

London, WC1N 3BG, United Kingdom

Location

MeSH Terms

Conditions

Migraine DisordersCluster Headache

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTrigeminal Autonomic Cephalalgias

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

July 14, 2011

First Posted

July 15, 2011

Study Start

August 1, 2011

Primary Completion

October 27, 2017

Study Completion

October 27, 2017

Last Updated

October 31, 2017

Record last verified: 2017-10

Locations